AstraZeneca adds ‘in vivo’ cell therapy capabilities with EsoBiotech deal

The British drugmaker is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer as well as autoimmune conditions.

Mar 17, 2025 - 15:10
 0
AstraZeneca adds ‘in vivo’ cell therapy capabilities with EsoBiotech deal

The British drugmaker is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer as well as autoimmune conditions.